Radiolabeled imaging agents for Alzheimer's disease
Jiajun Wu,
Kexin Li,
Jie Yang,
Meiting Mao,
Yan Cheng
Affiliations
Jiajun Wu
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu Sichuan province China
Kexin Li
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu Sichuan province China
Jie Yang
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu Sichuan province China
Meiting Mao
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu Sichuan province China
Yan Cheng
Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu Sichuan province China
Abstract Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disorder with long preclinical and prodromal phases in older people. Molecular imaging is a promising approach for noninvasive in vivo identification and tracking pathophysiological changes. In particular, nuclear neuroimaging in AD has extended beyond traditional evaluation of brain perfusion and glucose metabolism, and has achieved substantial progress over the past 2 decades. To gain a comprehensive understanding of nuclear neuroimaging with different targets in the brain, this review provides an overview of the literature on the current status and recent progress of the development of radioligands for definitive and differential diagnosis of AD.
